PMC:7195088 / 22175-22468 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"678","span":{"begin":144,"end":152},"obj":"Species"},{"id":"806","span":{"begin":14,"end":33},"obj":"Chemical"},{"id":"807","span":{"begin":38,"end":56},"obj":"Chemical"},{"id":"808","span":{"begin":61,"end":80},"obj":"Chemical"},{"id":"809","span":{"begin":109,"end":119},"obj":"Chemical"},{"id":"945","span":{"begin":158,"end":166},"obj":"Disease"}],"attributes":[{"id":"A678","pred":"tao:has_database_id","subj":"678","obj":"Tax:9606"},{"id":"A806","pred":"tao:has_database_id","subj":"806","obj":"MESH:C558899"},{"id":"A807","pred":"tao:has_database_id","subj":"807","obj":"MESH:D006886"},{"id":"A808","pred":"tao:has_database_id","subj":"808","obj":"MESH:C558899"},{"id":"A809","pred":"tao:has_database_id","subj":"809","obj":"MESH:C000606551"},{"id":"A945","pred":"tao:has_database_id","subj":"945","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T14","span":{"begin":277,"end":282},"obj":"Body_part"}],"attributes":[{"id":"A14","pred":"uberon_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":"Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T108","span":{"begin":158,"end":166},"obj":"Disease"}],"attributes":[{"id":"A108","pred":"mondo_id","subj":"T108","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T108","span":{"begin":259,"end":262},"obj":"http://purl.obolibrary.org/obo/CLO_0001608"}],"text":"Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T248","span":{"begin":14,"end":33},"obj":"Chemical"},{"id":"T249","span":{"begin":14,"end":23},"obj":"Chemical"},{"id":"T250","span":{"begin":24,"end":33},"obj":"Chemical"},{"id":"T251","span":{"begin":38,"end":56},"obj":"Chemical"},{"id":"T252","span":{"begin":61,"end":80},"obj":"Chemical"},{"id":"T253","span":{"begin":61,"end":70},"obj":"Chemical"},{"id":"T254","span":{"begin":71,"end":80},"obj":"Chemical"},{"id":"T255","span":{"begin":86,"end":96},"obj":"Chemical"},{"id":"T256","span":{"begin":97,"end":101},"obj":"Chemical"},{"id":"T257","span":{"begin":109,"end":119},"obj":"Chemical"}],"attributes":[{"id":"A248","pred":"chebi_id","subj":"T248","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A249","pred":"chebi_id","subj":"T249","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A250","pred":"chebi_id","subj":"T250","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A251","pred":"chebi_id","subj":"T251","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A252","pred":"chebi_id","subj":"T252","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A253","pred":"chebi_id","subj":"T253","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A254","pred":"chebi_id","subj":"T254","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A255","pred":"chebi_id","subj":"T255","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A256","pred":"chebi_id","subj":"T256","obj":"http://purl.obolibrary.org/obo/CHEBI_10545"},{"id":"A257","pred":"chebi_id","subj":"T257","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"}],"text":"Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15."}

{"project":"LitCovid-sentences","denotations":[{"id":"T164","span":{"begin":168,"end":221},"obj":"Sentence"},{"id":"T165","span":{"begin":222,"end":293},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15."}